What is semax, and is it FDA-approved?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10), modified by the addition of a Pro-Gly-Pro tripeptide extension. That modification serves two purposes: it improves metabolic stability (making the peptide resistant to rapid enzymatic breakdown) and eliminates the adrenal-stimulating activity of the parent ACTH fragment, so it does not trigger cortisol release. The result is a compound designed to retain the cognitive and neuroprotective effects researchers associate with ACTH without the hormonal side effects.
Semax has been registered as a pharmaceutical drug in Russia since 1994, where it carries approved indications for ischemic stroke recovery, cognitive impairment, and optic nerve atrophy, and is available as an intranasal spray. Outside Russia and Ukraine it has not been reviewed or approved by the FDA, EMA, or any major Western regulatory body. In the United States semax is not approved for any clinical use — any compound sold under that name is explicitly labeled as a research substance not intended for human use, meaning it falls outside regulatory standards for identity, purity, and sterility.
How does semax work? BDNF upregulation and neuroprotection
The most extensively studied mechanism is semax's effect on neurotrophin signaling. In animal models, semax upregulates the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — proteins critical to neuron survival, synaptic plasticity, and recovery from ischemic injury. After cerebral ischemia in rodents, semax activates transcription of neurotrophin genes and their receptor genes in the cortex within hours of administration, which researchers hypothesize underlies the neuroprotective effects observed in Russian clinical use.
A second mechanism is monoaminergic pathway activation. Research in rodents shows that semax activates dopaminergic and serotonergic brain systems — an effect that may contribute to the cognitive-enhancement and mood-related effects reported anecdotally in users and that partly parallels the nootropic framing given to the compound in Russian medicine. A 2014 genome-wide transcriptional study in a rat focal ischemia model found that semax predominantly enhanced expression of genes related to the immune system and vascular regulation at both 3 and 24 hours post-treatment, pointing to neuroinflammatory modulation as a third mechanism. All mechanistic evidence at this resolution comes from preclinical studies or Russian clinical data — not from large-scale Western randomized controlled trials.
What do research protocols show for semax dosing?
In the Russian clinical literature, semax is administered intranasally as a 0.1% or 1% aqueous solution. The 1% preparation, delivering approximately 100 mcg per drop, was used in stroke research at doses ranging from several hundred micrograms to a few milligrams per day, typically as 2–3 drops per nostril administered multiple times daily for 10-day treatment courses. The lower 0.1% concentration appears in cognitive-enhancement and attention-focused research contexts. Subcutaneous injection is mentioned in some research contexts but is less common than the intranasal route in published literature.
Because semax has not been reviewed or approved by the FDA, no dosing regimen has been validated by a Western regulatory body and there is no approved prescribing information for US clinicians to reference. Descriptions of dosing in research literature reflect what was used in specific Russian trials or preclinical studies under defined protocols — they are not FDA-approved guidance for individual use. Any clinical application outside an approved jurisdiction carries the uncertainties that apply to all unapproved compounds: unverified purity, unverified sterility, and no dose-response data generated in diverse human populations under controlled conditions. A licensed clinician who is familiar with the research literature determines any protocol.
What are the safety considerations?
Within the Russian clinical context, semax has generally been reported as well-tolerated at the doses used in its approved indications. The Pro-Gly-Pro modification was specifically designed to remove adrenal-stimulating activity, and the published Russian literature does not document systemic hormonal side effects. However, the available safety evidence is from studies that would not meet the size, design, and methodological standards required for FDA approval. No large-scale, placebo-controlled, independently audited safety trial has been completed in a Western regulatory context.
The absence of FDA approval carries practical consequences: no regulated supply chain, no post-market pharmacovigilance program, and no reviewed benefit-risk assessment for use outside Russia. Contamination, mislabeling, and dosing inaccuracy are real risks with research-use compounds obtained outside approved jurisdictions. Semax is not on any FDA compounding-approved list. Anyone encountering semax in a clinical context should discuss it with a licensed clinician who can evaluate the specific product source, the quality of the underlying evidence, and the individual patient's risk profile before any decision is made.
Tracking a semax protocol on PeptidePanel
PeptidePanel does not sell, source, supply, endorse, or prescribe semax or any other compound, and nothing on this page is medical advice. The educational nature of this content does not constitute an endorsement of semax use outside its approved jurisdiction. The decision to include any research compound in a clinical protocol — and at what dose, frequency, and duration — belongs to a licensed clinician who can weigh the available evidence against the individual patient's full medical history.
If a clinician has included semax in a protocol and tracking is in scope, PeptidePanel's protocol and biomarker logging tools provide a neutral, timestamped record of doses administered and any biomarker changes observed over time. That record supports continuity of care and gives both the patient and clinician a clear picture of what has been done and how markers have responded.